Aspergillus flavus originated pure compound as a potential antibacterial

Saeed Ullah Khattak1, Ghosia Lutfullah2, Zafar Iqbal3

  • 1Center of Biotechnology and Microbiology, University of Peshawar, Peshawar, KPK, Pakistan. Khattak@uop.edu.pk.

BMC Microbiology
|November 20, 2021
PubMed
Abstract

Insights

A novel compound from Aspergillus flavus shows promising antibacterial activity against multidrug-resistant bacteria. This fungal-derived compound, identified as (2E)-3-[(3S, 4R)-8-hydroxy-3, 4-dimethyl-1-oxo-3, 4-dihydro-1H-2-benzopyran-7-yl] prop-2-enoic acid, offers potential as a new drug lead.

Area of Science:

  • Microbiology and Natural Product Chemistry
  • Drug Discovery and Development

Background:

  • The rise of multidrug-resistant (MDR) bacteria poses a significant global health threat, necessitating the discovery of new antimicrobial agents.
  • Fungal secondary metabolites, like penicillin, have historically yielded crucial antibiotics, highlighting their potential for novel drug discovery.

Purpose of the Study:

  • To investigate the antibacterial potential of compounds isolated from Aspergillus flavus, a fungus found in the rhizosphere of Mentha piperetta.
  • To identify and characterize a specific bioactive compound from A. flavus for its potential as a drug lead against MDR pathogens.

Main Methods:

  • Isolation and identification of Aspergillus flavus from plant rhizosphere.
  • Extraction and purification of secondary metabolites using column chromatography.
  • Structure elucidation via Liquid Chromatography Mass Spectrometry (LCMS) and Nuclear Magnetic Resonance (NMR).
  • In silico docking studies against Staphylococcus aureus TyrRS (1JII).
  • In vitro antibacterial activity assessment using the agar well diffusion method against MDR Staphylococcus aureus and Proteus vulgaris.

Main Results:

  • A pure compound, (2E)-3-[(3S, 4R)-8-hydroxy-3, 4-dimethyl-1-oxo-3, 4-dihydro-1H-2-benzopyran-7-yl] prop-2-enoic acid (C14H14O5), was isolated and characterized.
  • In silico analysis indicated potential inhibition of S. aureus TyrRS with a docking score of -8.67 Kcal/mol.
  • In vitro testing showed significant antibacterial activity, with 58.8% inhibition against S. aureus and 28% against P. vulgaris at 1000 μg/mL.

Conclusions:

  • The isolated compound exhibits promising antibacterial properties against both Gram-positive and Gram-negative bacteria, particularly S. aureus.
  • This fungal-derived compound represents a potential candidate for further development into a novel antibiotic to combat MDR infections.
  • Further research is warranted to explore its full therapeutic potential and optimize its use as an antibiotic.